Targeting lung cancer to enhance immune response
Official title: Dual targeting of cGAS-STING and splicing to prime lung cancer immunogenicity
Funded at Brigham and Women's Hospital · NIH-10914651 · Data updated 2026-11-12
This study is exploring a new way to help people with non-small cell lung cancer, especially those with certain genetic changes, by using special treatments to boost their immune system and make their tumors more responsive to current therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 17, 2023 |
| Project end | July 16, 2025 |
| Funding year | 2024 |
| Award (this year) | $83,932 |
| NIH project number | 5F32CA284615-02 |
| Project ID | NIH-10914651 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with KRAS and STK11 mutations.
✕Less likely to help
Patients with other types of lung cancer or those who do not have the specific genetic mutations being targeted may not benefit from this research.
What this research studies
This research investigates a novel approach to improve treatment outcomes for patients with non-small cell lung cancer (NSCLC), particularly those with specific genetic mutations. The study aims to restore the immune response against lung cancer by using epigenetic agents to enhance the expression of a protein called STING, followed by targeted inhibition of a protein involved in cell division. By validating this strategy in clinical samples, the research seeks to determine if it can make resistant tumors more responsive to existing immunotherapies.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment options and survival rates for patients with resistant forms of lung cancer.
How similar studies have gone: Other research has shown promising results using similar approaches to enhance immune responses in cancer treatment, indicating potential for success in this study.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Gedeon, Patrick C — Brigham and Women's Hospital
- Study coordinator: Gedeon, Patrick C
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.